David Badcock has held strategic positions in the substance misuse treatment sector for over 15 years. During this time he has met and worked with thousands of individuals who have turned their lives around to lead healthy, successful lives free from the burden of drug and alcohol addiction. He was previously the Chief Executive Officer of Mainliners, a national organisation focusing on harm reduction and blood borne viruses, and also a senior manager at national drug treatment provider Addaction. In addition, David was a committee member for the Cambridge Ethnic Community Forum from 2002-2005, the chair of the Alliance (supporting people who receive prescribed medication for drug dependency) from 2007-2010, and scientific committee member for the influential London Joint Working Group for Substance Misuse and Hepatitis C from 2010-2015. David specialises in creating unique partnerships with organisations and companies who share a joined up vision to help the most marginalised and vulnerable members of our communities.
Anna Rickman has held executive positions in the public sector, startups, social enterprises, and impact-driven venture capital. She brings this breadth of experience to helping social purpose organisations grow. She is passionate about the role of business and technology in addressing the most pressing issues in society, particularly in changing peoples relationships with their own mental health, and increasing access to the most effective interventions. Previously, she designed and brought to market a digital storytelling platform for nonprofits and social enterprises at Lightful. She has also served on the board of Epic as Non-Executive Director, the largest youth services provider in West London, Co-Chaired the London chapter of the impact investment fund, Acumen, and is a fellow of the RSA. Prior to this she worked in East Africa mentoring Kenyan cooperatives to develop sustainable business models.
Anne Katrin Schlag is an Honorary Fellow at Imperial College London, having completed her graduate studies and PhD in Psychology at the London School of Economics and Political Science. Anne worked for several years as senior lecturer at King's College London where she was also co-director of AQUAMAX, an EU-wide study investigating public understandings of aquaculture. Her expertise ranges across the spectrums of risk perception, management and communication, mental models and social representations. She has a keen interest in the social, ethical and moral dimensions of national and international drug policies and related regulatory challenges. Her continuing research centres on the application of the MCDA approach to drug regulation, together with Prof David Nutt and Prof Larry Phillips.
Oli Stevens is a Research Associate and Manager at Imperial College London within the UNAIDS Reference Group for Estimates, Models and Projections. He previously completed postgraduate studies at the London School of Hygiene and Tropical Medicine and has a Masters in Immunology and Virology from the University of Oxford. His central interests are international health and drug policies, HIV, harm reduction, and chemsex.
Dr Pallab Seth is currently Managing Editor for Drug Science, Policy and Law and Journal of Psychopharmacology with Prof David J Nutt (Editor-in-Chief) in the Division of Brain Sciences, Faculty of Medicine at Imperial College. He joined Imperial in 2006. He has Postdoctoral training in the laboratories of Professor Kenneth J Smith and Professor Sandra E File at King’s College London. His past editorial experiences were as a Managing Editor, Pharmacology, Biochemistry and Behavior (an Elsevier Journal) with Prof Sandra E File and Journal of Neuroendocrinology (a Wiley-Blackwell Publishing Journal) with Professor Julia Buckingham. Prior to this, Pallab graduated from Presidency College, Calcutta and post-graduation from Calcutta University with a First Class in Physiology and then awarded a PhD in 1995 (Jadavpur University) in electrophysiological investigations of dopaminergic influence on spinal neurotransmission from the Pharmacology Division of Indian Institute of Chemical Biology (a CSIR institute, Govt of India) under the supervision of Dr Dilip K Ganguly.